AstraZeneca Receives FDA Approval for Orpathys in MET Exon 14 Skipping NSCLC

AstraZeneca today announced that the FDA has approved Orpathys (savolitinib) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have MET exon 14 skipping alterations. Savolitinib is a highly selective MET kinase inhibitor. In the Phase 2 VISION trial, savolitinib demonstrated an overall response rate of 44% in patients with MET exon 14 skipping NSCLC. The median duration of response was 9.9 months. This approval provides a new targeted treatment option for patients with this specific molecular subtype of NSCLC, which accounts for approximately 3-4% of all NSCLC cases.